,irinotecan,trastuzumab deruxtecan
ipsen,daiichi sankyo,astrazeneca
[]
important to remember that the chemo payload in t-dxd is a topoisomerase i inhibitor not dissimilar to irinotecan so, while being appropriately vigilant for ild, cannot forget to monitor for enteric toxicity below the diaphragm too #asco22 
Mark Lewis, MD, (@marklewismd) #GISM Oncologist from @Intermountain, takes over our Twitter today to discuss #ASCO22.